Somewhat Favorable News Coverage Somewhat Unlikely to Impact Depomed (DEPO) Share Price

News headlines about Depomed (NASDAQ:DEPO) have trended somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Depomed earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news articles about the specialty pharmaceutical company an impact score of 45.9259437935475 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

These are some of the news articles that may have impacted Accern’s scoring:

Several research firms have recently commented on DEPO. Royal Bank Of Canada decreased their target price on shares of Depomed from $13.00 to $10.00 and set a “sector perform” rating for the company in a research report on Tuesday, August 8th. Piper Jaffray Companies reissued a “neutral” rating and set a $9.00 target price (down from $10.00) on shares of Depomed in a research report on Wednesday, August 9th. Janney Montgomery Scott downgraded shares of Depomed from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $18.00 to $8.00 in a research report on Tuesday, August 8th. UBS AG boosted their target price on shares of Depomed from $6.00 to $7.00 and gave the stock a “neutral” rating in a research report on Friday, November 10th. Finally, Mizuho reissued a “neutral” rating and set a $6.00 target price (down from $11.00) on shares of Depomed in a research report on Friday, October 13th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and two have issued a buy rating to the stock. Depomed has an average rating of “Hold” and a consensus target price of $10.64.

Depomed (NASDAQ DEPO) opened at $6.18 on Friday. Depomed has a twelve month low of $4.31 and a twelve month high of $21.38. The company has a debt-to-equity ratio of 2.90, a current ratio of 0.83 and a quick ratio of 0.79.

Depomed (NASDAQ:DEPO) last released its quarterly earnings results on Tuesday, November 7th. The specialty pharmaceutical company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.02. Depomed had a negative net margin of 27.73% and a negative return on equity of 51.07%. The business had revenue of $95.40 million for the quarter, compared to analysts’ expectations of $99.11 million. During the same period in the previous year, the company earned $0.28 earnings per share. The firm’s revenue for the quarter was down 13.7% compared to the same quarter last year. equities research analysts forecast that Depomed will post -1.34 earnings per share for the current year.

WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Depomed (DEPO) Share Price” was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://stocknewstimes.com/2017/11/19/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-depomed-depo-share-price.html.

Depomed Company Profile

Depomed, Inc is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl).

Insider Buying and Selling by Quarter for Depomed (NASDAQ:DEPO)

Receive News & Ratings for Depomed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply